These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 1690824)
1. [M-BACOD in advanced case of non-Hodgkin's lymphoma]. Itami J; Ogata H; Shimizu K; Nemoto K; Yasuda S; Yoshida H; Mikata A; Arimizu N Gan No Rinsho; 1990 Mar; 36(4):499-504. PubMed ID: 1690824 [TBL] [Abstract][Full Text] [Related]
2. The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Canellos GP; Skarin AT; Klatt MM; Rosenthal DS; Case DC; Pinkus GS; Jochelson MS; Yeap BY; Shipp MA Semin Hematol; 1987 Apr; 24(2 Suppl 1):2-7. PubMed ID: 2438777 [TBL] [Abstract][Full Text] [Related]
3. A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas. Guglielmi C; Gherlinzoni F; Amadori S; Mazza P; Mantovani L; Lauria F; Martelli M; Zinzani PL; Greco V; Poletti G Haematologica; 1989; 74(6):563-9. PubMed ID: 2483401 [TBL] [Abstract][Full Text] [Related]
4. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study. Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168 [TBL] [Abstract][Full Text] [Related]
5. [Provisional treatment results of intensive combination chemotherapy (m-BACOD) in non-Hodgkin lymphoma of intermediate and high malignancy]. Knecht H; Streuli RA; Odermatt BF; Rhyner K Schweiz Med Wochenschr; 1987 Dec; 117(50):2038-41. PubMed ID: 2448874 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577 [TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies. Anderson KC; Skarin AT; Rosenthal DS; MacIntyre JM; Pinkus GS; Case DC; Leonard RC; Canellos GP Cancer Treat Rep; 1984 Nov; 68(11):1343-50. PubMed ID: 6209007 [TBL] [Abstract][Full Text] [Related]
8. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Kaplan LD; Straus DJ; Testa MA; Von Roenn J; Dezube BJ; Cooley TP; Herndier B; Northfelt DW; Huang J; Tulpule A; Levine AM N Engl J Med; 1997 Jun; 336(23):1641-8. PubMed ID: 9171066 [TBL] [Abstract][Full Text] [Related]
9. [CHOP-bleo versus m-BACOD in the treatment of intermediate and high-grade malignant lymphomas]. Avilés A; Huerta J; Guzmán R; Zepeda G; Díaz-Maqueo JC Rev Invest Clin; 1990; 42(4):271-6. PubMed ID: 1708910 [TBL] [Abstract][Full Text] [Related]
11. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169 [TBL] [Abstract][Full Text] [Related]
12. [Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, prednisolone (VEPA) in non-Hodgkin's lymphoma, with special reference to correlation of surface phenotype with response and survival]. Chubachi A; Miura AB; Yamaguchi A; Nishimura S Gan To Kagaku Ryoho; 1988 Jul; 15(7):2057-63. PubMed ID: 3293535 [TBL] [Abstract][Full Text] [Related]
13. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619 [TBL] [Abstract][Full Text] [Related]
14. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis. Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406 [TBL] [Abstract][Full Text] [Related]
15. [Bleomycin, adriamycin, cyclophosphamide, vincristine, deacadron, etoposide (BACOD-E) chemotherapy for the treatment of non-Hodgkin's lymphoma: long-term survival rate and complications]. Isobe K; Yasuda S; Itami J; Hara R; Machida N; Aruga T; Uchida Y; Kuyama J; Yamamoto S; Kimura S; Motoori K; Ito H Nihon Igaku Hoshasen Gakkai Zasshi; 1998 Jun; 58(7):360-5. PubMed ID: 9711076 [TBL] [Abstract][Full Text] [Related]
16. [Malignant lymphomas in HIV-infected patients]. Adam H; Flepp M; Schüler G; Egli F; Greminger P; Lüthy R; Rhyner K Schweiz Med Wochenschr; 1988 Nov; 118(45):1651-6. PubMed ID: 2460919 [TBL] [Abstract][Full Text] [Related]
17. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. Shipp MA; Yeap BY; Harrington DP; Klatt MM; Pinkus GS; Jochelson MS; Rosenthal DS; Skarin AT; Canellos GP J Clin Oncol; 1990 Jan; 8(1):84-93. PubMed ID: 1688615 [TBL] [Abstract][Full Text] [Related]
18. Phase III comparative trial (m-BACOD v m-BNCOD) in the treatment of stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology. Gherlinzoni F; Guglielmi C; Mazza P; Amadori S; Mandelli F; Tura S Semin Oncol; 1990 Dec; 17(6 Suppl 10):3-8; discussion 8-9. PubMed ID: 1701924 [TBL] [Abstract][Full Text] [Related]
19. Results of three polychemotherapy programs in non-Hodgkin's lymphomas. Konopka L; Pawelski S J Chemother; 1989 Jul; 1(4 Suppl):1259-62. PubMed ID: 16312857 [No Abstract] [Full Text] [Related]
20. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL). Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]